Circ Cardiovasc Qual
-
Circ Cardiovasc Qual · Mar 2014
Randomized Controlled Trial Multicenter Study Comparative StudyRepresentativeness of RELAX-AHF clinical trial population in acute heart failure.
The Relaxin for the Treatment of Acute Heart Failure (RELAX-AHF) trial enrolled 1161 patients admitted to the hospital for acute heart failure (AHF) to evaluate the therapeutic efficacy of serelaxin, a recombinant form of human relaxin-2. We characterized how representative RELAX-AHF clinical trial enrollees were to those patients with AHF found in international registries. ⋯ Patients potentially eligible for RELAX-AHF represent ≈2 in 10 patients with AHF in the United States, Latin America, or Asia-Pacific. These patients differ significantly from other hospitalized patients based on clinical characteristics and outcomes.